Anastrozole - Award
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-D-0016
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice pertaining to the pharmaceutical product Anastrozole. This notice, identified by procurement number SPE2D2-25-D-0016, announces the execution of a modification for Option Year One of an existing contract. The primary objective of this procurement activity is to ensure the continued supply of Anastrozole, a medication commonly used in the treatment of hormone receptor-positive breast cancer, thereby supporting the medical readiness and healthcare needs of military personnel and associated beneficiaries.
The scope of this contract encompasses the manufacturing and delivery of pharmaceutical preparations, as classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals). The place of performance for this contract is Kfar Saba, Israel, indicating that the manufacturing or supply operations are based in this location. This international aspect may require contractors to have established capabilities for global logistics, regulatory compliance, and quality assurance in pharmaceutical production.
The intended outcome of this procurement is the reliable and timely provision of Anastrozole, ensuring that the DLA Troop Support can maintain adequate inventory levels to meet ongoing and emergent medical requirements. Key deliverables include the consistent supply of the specified pharmaceutical product in accordance with the terms and conditions outlined in the contract and its modifications.
The contracting entity for this award is DLA Troop Support, a federal office within the Defense Logistics Agency. The primary points of contact for this procurement are Nancy Fernandez ([email protected], 445-737-0713) and Jason Wray ([email protected], 445-737-6304), who can provide further information regarding contract administration and technical requirements.
This procurement is classified as an award notice, indicating that the contract has already been executed and is currently active. The notice does not specify any set-aside requirements or special considerations such as small business preferences or socioeconomic program participation. Contractors interested in similar future opportunities should note the importance of compliance with federal pharmaceutical manufacturing standards and the ability to operate or coordinate with facilities in Israel.
For additional details, including the official modification document for Option Year One, interested parties are directed to the official notice on SAM.gov (Opportunity ID: 3e4a810289544fd69b71139b71af35ea), where attachments related to the award are available for review.
In summary, this award notice reflects the DLA Troop Support’s ongoing commitment to securing high-quality pharmaceutical products for defense-related healthcare needs, with a focus on international supply chain reliability and regulatory compliance.